EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation

Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, Prapti A Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D Anderson, Farrukh T Awan und 5 weitere

Acta Medica Academica · 2023

DOI: 10.5644/ama2006-124.399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Medica Academica, 2023. Verfasst von Fieke W Hoff und 16 weiteren Autor:innen. Beteiligte Einrichtung: Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.

Methods

Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.

Results

Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.

Conclusion

Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hematologic NeoplasmsHumansCOVID-19 VaccinesImmunoglobulin GSARS-CoV-2Antibody FormationVaccination

Stichwörter der Autor:innen

Antibody ResponseHematologic MalignancySARS-CoV-2 Vaccination

Substanzen

COVID-19 VaccinesImmunoglobulin G

Autor:innen und Institutionen

  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA.
  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, USA. yazan.madanat@utsouthwestern.edu.

Zitieren

APA

Hoff, F. W., Goksu, S. Y., Premnath, N., Patel, P. A., Ikpefan, R., Kaur, G., Vusirikala, M., Bat, T., Chen, W., Geethakumari, P. R., Anderson, L. D., Awan, F. T., Collins, R. H., Weinberg, O. K., Muthukumar, A., Chung, S. S., & Madanat, Y. F. (2023). SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation. Acta Medica Academica. https://doi.org/10.5644/ama2006-124.399

Vancouver

Hoff FW, Goksu SY, Premnath N, Patel PA, Ikpefan R, Kaur G, et al. SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation. Acta Medica Academica. 2023. doi:10.5644/ama2006-124.399

BibTeX
@article{Hoff2023,
  author = {Hoff, Fieke W and Goksu, Suleyman Y and Premnath, Naveen and Patel, Prapti A and Ikpefan, Ruth and Kaur, Gurbakhash and Vusirikala, Madhuri and Bat, Taha and Chen, Weina and Geethakumari, Praveen Ramakrishnan and Anderson, Larry D and Awan, Farrukh T and Collins, Robert H and Weinberg, Olga K and Muthukumar, Alagarraju and Chung, Stephen S and Madanat, Yazan F},
  title = {SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation},
  journal = {Acta Medica Academica},
  year = {2023},
  doi = {10.5644/ama2006-124.399}
}
Kostenlos starten →